Tolebrutinib

DB18715InvestigationalSmall molecule

Tolebrutinib: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₂₆H₂₅N₅O₃ · 455.518 g/mol (avg)
Also known as: 2h-imidazo(4,5-c)pyridin-2-one, 4-amino-1,3-dihydro-1-((3r)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl)-3-(4-phenoxyphenyl)- · 4-amino-1,3-dihydro-1-((3r)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl)-3-(4-phenoxyphenyl)-2h-imidazo(4,5-c)pyridin-2-one
Code names: PRN-2246 · SAR-442168

Resolves to

Compound

Structure

InChIKeyKOEUOFPEZFUWRF-LJQANCHMSA-NSMILESNC1=C2N(C(=O)N([C@@H]3CCCN(C3)C(=O)C=C)C2=CC=N1)C1=CC=C(OC2=CC=CC=C2)C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tolebrutinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.